Evidence map›Paper›PMID 40676613›Full record

ReviewCell communication and signaling : CCS2025

Targeting androgen receptor stability and degradation: approaches for developing a therapy for spinal and bulbar muscular atrophy.

Riccardo Cristofani, Barbara Tedesco, Veronica Ferrari, Marta Chierichetti, Marta Cozzi, Paola Pramaggiore, Laura Cornaggia, Ali Mohamed, Elena Casarotto, Maria Brodnanova and 7 more

Abstract readReview
In one paragraph

Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Riccardo CristofaniDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy. riccardo.cristofani@unimi.it.
Barbara TedescoDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Veronica FerrariDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Marta ChierichettiDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Marta CozziDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Paola PramaggioreDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Laura CornaggiaDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Ali MohamedDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Elena CasarottoDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Maria BrodnanovaDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Rocio MagdalenaDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Prashant KoshalDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Margherita PiccolellaDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Valeria CrippaDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Mariarita GalbiatiDipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.
Angelo Poletti *Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy. angelo.poletti@unimi.it.
Paola Rusmini *Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti", Dipartimento di Eccellenza (2018-2027), Università degli Studi di Milano, Milan, 20133, Italy.

Funding

Mechanistic and Translational Investigations of HSPB8-associated dominant rimmed vacuolar myopathyR21AR080407 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI KIMONIS, VIRGINIA EUNICE · 2024 to 2024
$369k
AFM Telethon, France 23236Fondazione Cariplo 2021-1544Fondazione Telethon GGP19128Kennedy's Disease Association 2018 grantKennedy's Disease Association 2020 grantMinistero dell'Università e della Ricerca PRIN n. 2020PBS5MJMinistero dell'Università e della Ricerca PRIN n. 2022EFLFL8Ministero dell'Università e della Ricerca PRIN PNRR P2022B5J32NIAMS NIH HHS R21 AR080407NIAMS NIH HHS R21AR080407Università degli Studi di Milano piano di sviluppo della ricerca (PSR) UNIMI -linea B
6 · The paper itself

Abstract

Conformational changes of proteins can occur due to mutations or stress conditions, altering their functionality through loss of physiological or gain of pathological function. A Protein Quality Control (PQC) system exists in cells to deal with the accumulation of misfolded proteins and aggregates, comprising a network of chaperones and degradative pathways to refold or remove the aberrant proteins. Protein misfolding and PQC system impairment lead to a broad range of diseases, including neurodegenerative and neuromuscular disorders, among them spinal and bulbar muscular atrophy (SBMA). SBMA is a neuromuscular disorder caused by a polyglutamine expansion (polyQ) in the androgen receptor (AR) protein. Expanded AR (ARexp) is highly prone to misfolding and aggregation, leading to its accumulation in affected tissues. Here, we summarise the dynamics that control AR protein stability and its degradation in physiological conditions. Next, we recapitulate the current knowledge of the molecular mechanisms of SBMA pathogenesis involving the PQC system. Finally, we provide an overview of promising approaches to SBMA intervention involving the modulation of PQC system functions to reduce ARexp accumulation and its toxic effects in affected cells.

Indexed as

Bulbo-Spinal Atrophy, X-LinkedMuscular Atrophy, SpinalProteolysisReceptors, AndrogenAnimalsHumansPeptidesProtein StabilityPeptidespolyglutamineReceptors, AndrogenAndrogen receptorAutophagyDegradationPolyglutamine

Identifiers

PMID40676613
PMCPMC12273273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.